Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Study to assess the effect of Telmisartan on diastolic and systolic blood pressure and to establish the effect on patient's quality of life scores.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Telmisartan low dose | Experimental |
| |
| Telmisartan high dose | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Low dose of telmisartan | Drug |
| ||
| High dose of telmisartan |
| Measure | Description | Time Frame |
|---|---|---|
| Change in diastolic blood pressure | Pre-dose, up to 6 weeks after start of treatment | |
| Change in systolic blood pressure | Pre-dose, up to 6 weeks after start of treatment | |
| Changes from baseline in the quality of life (QOL) scores by patient self-assessment | Pre-dose, 6 weeks after start of treatment |
| Measure | Description | Time Frame |
|---|---|---|
| Assessment of blood pressure control rate | Up to 6 weeks after start of treatment | |
| Assessment of systolic blood pressure response rate | Up to 6 weeks after start of treatment | |
Not provided
Inclusion Criteria:
Exclusion Criteria:
- Females of childbearing potential
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D006973 | Hypertension |
| ID | Term |
|---|---|
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D000077333 | Telmisartan |
| ID | Term |
|---|---|
| D001713 | Biphenyl Compounds |
| D001555 | Benzene Derivatives |
| D006841 | Hydrocarbons, Aromatic |
| D006844 | Hydrocarbons, Cyclic |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Drug |
|
| Assessment of diastolic blood pressure response rate |
| Up to 6 weeks after start of treatment |
| Change from baseline in pulse pressure | Pre-dose, up to 6 weeks after start of treatment |
| Number of patients with adverse events | Up to 6 weeks |
| D006838 |
| Hydrocarbons |
| D009930 | Organic Chemicals |
| D001562 | Benzimidazoles |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D006571 | Heterocyclic Compounds |